索拉菲尼联合放疗治疗原发性肝癌的研究进展  

Sorafenib combined with radiotherapy for primary hepatic carcinoma

作　　者：李广欣[1] 张建忠[1] 黎功[1] 

机构地区：[1]武警北京总队第三医院肿瘤科,100141

出　　处：《国际肿瘤学杂志》2012年第8期615-618,共4页Journal of International Oncology

摘　　要：适形放疔是原发性肝癌局部治疗的重要手段之一，但放疗后肝内、肝外转移率较高。索拉菲尼是目前肝癌治疗中惟一被证实有效的药物，可提高晚期肝癌患者的总生存期。索拉菲尼联合放疗，可提高肿瘤细胞辐射敏感性、抑制血管生成、缓解肿瘤乏氧状态、使细胞周期同步化。索拉菲尼联合放疗，已进行了大量生物学研究，I、Ⅱ期临床试验也正在开展。Conformal radiotherapy is an important therapeutic strategy for primary hepatic carcinoma, which has high local control rate. However, the frequency of intra- and extra-hepatic recurrences is very high.Sorafenib is the only drug that has been demonstrated effectiveness to increase overall survival in advanced or metastatic hepatocellular carcinoma. The combination about radiotherapy and sorafenib can increase the radio- sensitiveness, and inhibit the angiogenesis,and relieve the hypoxia, as well as synchronize the cell cycle. A lot of biological studies of sorafenib combined with radiotherapy have been carried out, and the phase I - II clinical trials are is in progress.

关 键 词：放射疗法 肝肿瘤 索拉菲尼 

分 类 号：R735.7[医药卫生—肿瘤]